ReCode Therapeutics Reports Initial Dosing of Subjects in Phase 1 Trial for Inhaled mRNA Therapy, RCT2100, Aimed at Cystic Fibrosis Treatment.

Upadacitinib acts as an ATP-competitive JAK inhibitor; it competes with ATP and blocks nucleotide binding to inhibit kinase activity and the phosphorylation of downstream effectors.

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development has initiated dosing in the early-stage ALETA-001 clinical study, targeting individuals with recurrent or unresponsive B-cell cancers.

Dextromethorphan (DXM) is a synthetic analog of codeine, but unlike codeine, it is not a narcotic and does not have the same potential for abuse or addiction.

FDA has sanctioned a biweekly administration of TECVAYLI® (teclistamab-cqyv) as a therapeutic option for those suffering from recurring or unresponsive multiple myeloma.

On January 24, 2024, Novo Nordisk partnered with EraCal Therapeutics to co-develop an appetite and weight control drug.

The experimental biosimilar by Polpharma Biologics demonstrates similar pharmacokinetics and dynamics to the top-selling IBD medication, Entyvio®.

Acyclovir, sold as ZOVIRAX, is a synthetic drug that inhibits herpes viruses, including HSV-1, HSV-2, and VZV, both in lab and living organisms.

Voyager Therapeutics Announces Promising Early-Stage Results for Gene Therapy Aimed at Attenuating Tau in Alzheimer's, Pushes Project into Later Research Phase.

Hospitalization data for darolutamide/docetaxel in metastatic prostate cancer were presented at 2024 ASCO_GU on Jan 25, comparing daro/docetaxel/ADT with placebo/docetaxel/ADT.

Immune-Onc Therapeutics Discloses a Partnership for Clinical Research, Assessing IO-108 in an International Early Phase Trial Aimed at Initial Therapy for Progressive Hepatic Carcinoma.

CELEBREX (celecoxib) is a nonsteroidal anti-inflammatory drug. Celecoxib has analgesic, anti-inflammatory, and antipyretic properties.